House members voice opposition to CMS reprints stance

Share this article:
Jonathan Blum
Jonathan Blum

Nearly two dozen members of Congress signaled solidarity with 41 medical boards and 33 physician associations in opposing the inclusion of textbooks and reprints in Sunshine Act reporting. The 23 House members—seven of them physicians—sent a letter to CMS to voice disagreement with an HHS decision to include textbooks and journals as “transfers of value” reportable under the Physician Payment Sunshine Act.  

“Ad agency and publisher representatives will continue to meet with government and industry leaders to pursue a quick resolution of the issues,” said John Kamp, executive director, Coalition for Healthcare Communication (CHC), which partnered with the American Medical Association in the effort.

“We've been disappointed so far,” Kamp told MM&M as this issue went to press, adding that advocates of the change were planning to meet with Jonathan Blum, CMS deputy administrator and director.

Failing that, said Kamp, they will attempt “a short line in one of the pieces of legislation expected to move [in 2014].”

The letter co-signers included seven Democrats and 16 Republicans. They stated, CMS's take that reprints and textbooks are not one of the exclusions from the reporting requirements “is inconsistent with the statutory language on its face, congressional intent, and the reality of clinical practice where patients benefit directly from improved physician medical knowledge.”

The decision also “presents a clear disincentive for clinicians to accept high-quality, independent educational materials,” they added in the letter.

Share this article:

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...